Both Pfizer and Moderna are working on vaccines that target Omicron, but will this help us control COVID?


By late 2021, most Australians had been double-vaccinated against COVID-19. The high vaccination rates provided some confidence that the threat from the pandemic was subsiding. But, unfortunately, by mid-December, this optimism had been swept away by a surge of Omicron infections. The key points from this article:

  • Emerging research shows there is only about 20 per cent protection from Omicron infection four months after two doses of AstraZenecaPfizer or Moderna vaccines (though protection against hospitalisation and death remains much higher).

  • A booster dose increases protection against infection, but possibly only short-term.

  • Since the emergence of Omicron, both Pfizer and Moderna has announced they're working on vaccines to target the variant, with production promised as early as March 2022.

  • Variant-specific vaccines are a reactive measure. By the time we roll out any variant-specific vaccine, that variant may have peaked, and a new variant will likely be on the way.


Recent Runway Posts related to this topic:

References from the Web:

Source Information ABC-Australia: